Changeflow GovPing Pharma & Drug Safety ACME UNITED CORPORATION Class II Drug Recall D-...
Urgent Enforcement Added Final

ACME UNITED CORPORATION Class II Drug Recall D-0358-2026

Favicon for changeflow.com FDA: Drug Recalls Class II
Filed March 11th, 2026
Detected March 28th, 2026
Email

Summary

The FDA has initiated a Class II drug recall (D-0358-2026) for ACME UNITED CORPORATION's First Aid Only BZK Antiseptic Towelettes due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects a nationwide distribution within the United States.

What changed

The FDA has issued a Class II drug recall (D-0358-2026) for ACME UNITED CORPORATION's BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%, 100 Wipes, NDC 0924-7116-04). The recall is due to Current Good Manufacturing Practice (CGMP) deviations and affects nationwide distribution within the United States. The recall is ongoing as of March 11, 2026.

Drug manufacturers and distributors involved in the supply chain of this product must immediately identify and segregate affected inventory. Compliance officers should review their CGMP adherence and distribution records to ensure no further issues arise and to cooperate with any FDA requests related to this recall. Failure to comply with recall procedures can result in further enforcement actions.

What to do next

  1. Identify and segregate affected product inventory
  2. Review CGMP adherence and distribution records
  3. Cooperate with FDA requests related to the recall

Source document (simplified)

ACME UNITED CORPORATION

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0358-2026 · 20260311 · Ongoing

Product

First Aid Only BZK Antiseptic Towelettes (Benzalkonium Chloride 0.13%) 100 Wipes, NDC 0924-7116-04

Reason for Recall

CGMP Deviations

Distribution

Nationwide within the United States

Source: openFDA Enforcement API

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Filed
March 11th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0358-2026

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Recalls CGMP Compliance
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Product Safety Manufacturing Compliance

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when FDA: Drug Recalls Class II publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.